Name
RF7-06: Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden - Commentary by: Adam Brufsky, MD, PhD
Date & Time
Wednesday, December 3, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL